Brief Recent History
NF was manufactured in the 1970s by Bayer -as Lampit®- but its
development started earlier, in the 1960s as Bayer-2502. Similar to what
happened with BZN, Bayer discontinued production in the 1990s due to low
demand and almost null profitability, but reconsidered and restarted
production later. Since then, country-level access to the drug has
depended on individual states’ agreements and negotiations with WHO and
Bayer, and local bureaucratic and political decisions. Availability
currently seems erratic in many South American countries, but it is
expected to improve in the near future, after a clinical trial performed
in children -CHICO study (NCT02625974) - that supported FDA approval of
NF formulations for CD in the pediatric population.